Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients

Yi Long Wu, Yan Sun, Cai Cun Zhou, Li Zhang, Shi Ying Yu, Sheng Lin Ma, Ling Lucia Han, Xiao Qing Rosetta Zhang, Orlando Mauro

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background The efficacy of pemetrexed in the second-line treatment of Chinese patients with advanced non-small cell lung cancer (NSCLC) has been shown to be similar to that of docetaxel in a recent study; additionally, pemetrexed was associated with much better safety and toxicity profiles. Here, the survival without common toxicity criteria grade 3/4 toxicity (SWT) data from a post hoc analysis of this recent prospective NSCLC study in Chinese patients is reported. This post hoc analysis differs from the main study; it focuses on the nonsquamous population to align with the current approval for pemetrexed in China. Methods A total of 154 patients with nonsquamous NSCLC received either pemetrexed (500 mg/m2 intravenously (IV)) or docetaxel (75 mg/m2 IV) on day 1 of 21-day cycles. SWT was analyzed using Kaplan-Meier and univariate Cox methods. Results Patients treated with pemetrexed had a longer median SWT than patients treated with docetaxel (7.4 months versus 1.2 months; unadjusted hazard ratio =0.59, 95% confidence interval (CI): 0.41-0.84; P=0.003). At 12 and 18 months, the SWT event-free probability for pemetrexed patients (18 months: 24.5%, 95%CI 13.9%-36.6%, vs. 12.3%, 95% CI 4.8%-23.6%) was greater than that for docexatel patients (12 months: 37.3%, 95% CI 26.5%- 48.0%, vs. 23.3%, 95% CI 14.4-33.4). The progressionfree survival without common toxicity criteria grade 3/4 toxicity (PFS-WT) was also statistically significantly longer for patients treated with pemetrexed than patients treated with docetaxel (1.9 months vs. 1.1 months, P=0.002). Conclusions Chinese patients with nonsquamous NSCLC disease treated with pemetrexed had improved SWT beyond 6 months than those receiving docetaxel. This analysis supports a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of Chinese nonsquamous NSCLC patients.

Original languageEnglish
Pages (from-to)4624-4628
Number of pages5
JournalChinese Medical Journal
Volume126
Issue number24
DOIs
StatePublished - 2013

Keywords

  • Chinese patient
  • Non-small cell lung cancer
  • Pemetrexed
  • Survival without toxicity

Fingerprint

Dive into the research topics of 'Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients'. Together they form a unique fingerprint.

Cite this